FuzzyBot: Importing a new version from external source

2024-02-12T10:46:17Z

Importing a new version from external source

New page

In May 2015, the [[FDA]] issued a warning that gliflozins can increase risk of [[diabetic ketoacidosis]] (DKA, a serious condition in which the body produces high levels of blood acids called ketones). By reducing glucose blood circulation, gliflozins cause less stimulation of endogenous [[insulin]] secretion or lower dose of exogenous insulin that results in diabetic ketoacidosis. They can specifically cause ''euglycemic'' DKA (euDKA, DKA where the blood sugar is not elevated) because of the renal tubular absorption of ketone bodies. A particularly high risk period for ketoacidosis is the perioperative period. SGLT2 inhibitors may need to be discontinued before surgery, and only recommended when someone is not unwell, is adequately hydrated and able to consume a regular diet. Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing. To lessen the risk of developing ketoacidosis after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. [[Canagliflozin]], [[dapagliflozin]], and [[empagliflozin]] should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery.

Translations:SGLT2 inhibitor/8/en - Revision history

FuzzyBot: Importing a new version from external source